Does intravenous bosentan improve hemodynamics in patients with severe pulmonary hypertension?
Intravenous bosentan is a potent pulmonary vasodilator in severe pulmonary hypertension, but its clinical utility via this route is limited by systemic hypotension.
Intravenous bosentan is a potent but nonselective pulmonary vasodilator at the doses tested, even in patients resistant to inhaled nitric oxide. Transient increases in plasma ET-1 were observed, consistent with a blockade of endothelial ET(B) receptors. Systemic hypotension and other significant events during the study indicate that its intravenous use in patients with severe PHT may be limited. Implications for future trial design and studies of chronic oral treatment are discussed.
Williamson et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: